Analyst Rating: Will SAGE Therapeutics Inc (SAGE) Stock Outperform the Market?

Monday, November 01, 2021 10:58 AM | InvestorsObserver Analysts

Mentioned in this article

Wall Street is positive on SAGE Therapeutics Inc (SAGE). On average, analysts give SAGE a Buy rating. The average price target is $77.368, which means analysts expect the stock to increase by 82.47% over the next twelve months. That average ranking earns SAGE an Analyst Rating of 27, which is better than 27% of stocks based on data compiled by InvestorsObserver.

Wall Street analysts are rating SAGE a Buy today. Find out what this means to you and get the rest of the rankings on SAGE!
See Full SAGE Report

Why are Analyst Ratings Important?

A company's financial statements are a significant factor weighted by experts when analyzing a company's health. Beyond just the numbers, analysts follow specific industries closely and are able to gain a detailed understanding of how a storm in one part of the world can shutdown supply chains leading to a change in consumption across the globe. This knowledge allows investors to respond to potential changes in the market before they are revealed in a quarterly annoucement. InvestorsObserver averages the ratings across all these analysts and percentile ranks those averages. This allows you to compare stocks in greater detail than the usual five-tiered system used amongst the majority of investors.

What's Happening With SAGE Therapeutics Inc Stock Today?

SAGE Therapeutics Inc (SAGE) stock is higher by 5.05% while the S&P 500 has fallen -0.14% as of 10:56 AM on Monday, Nov 1. SAGE has risen $2.04 from the previous closing price of $40.36 on volume of 124,131 shares. Over the past year the S&P 500 is higher by 38.93% while SAGE has fallen -40.85%. SAGE earned $11.84 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 3.58. Click Here to get the full Stock Report for SAGE Therapeutics Inc stock.

Share this article:

Related Articles